Masimo Corporation(MASI) Stock Research - Grey Stern Research
Loading...

Masimo Corporation (MASI) Stock Analysis

$124.10 (2.89%)

MASI Financial Performance


Use the table below to view Masimo Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2023

Metric Value Ranking among Peers
Price $120.61 -
52 Week Low $75.22 -
52 Week High $169.58 -
Market Cap $6.4 Billion 5/13
Gross Margin 48% 12/13
Profit Margin 6% 5/13
EBITDA margin 8% 6/13
Q4 - 2023 Revenue $548.9 Million 2/13
Q4 - 2023 Earnings $34.0 Million 5/13
Q4 - 2023 Free Cash Flow $44.2 Million 3/13
Trailing 4 Quarters Revenue $2.0 Billion 2/13
Trailing 4 Quarters Earnings $81.6 Million 6/13
Quarterly Earnings Growth -17% 10/13
Annual Earnings Growth -47% 9/13
Quarterly Revenue Growth -11% 12/13
Annual Revenue Growth -10% 12/13
Cash On Hand $163.0 Million 8/13
Short Term Debt $0 11/13
Long Term Debt $871.7 Million 4/13

Masimo Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Masimo Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 78.46 3/13
PS 3.13 10/13
PB 4.69 10/13
PC 39.28 8/13
Liabilities to Equity 1.23 7/13
ROA 0.03 6/13
ROE 0.06 6/13
Current Ratio 1.81 7/13
Quick Ratio 0.10 11/13
Long Term Debt to Equity 0.64 8/13
Debt to Equity 0.64 9/13
Burn Rate 187.79 1/13
Cash to Cap 0.03 6/13
CCR 1.30 2/13
EV to EBITDA 161.26 7/13
EV to Revenue 3.47 10/13

Company Details

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.

CEO: Mr. Joseph Kiani

Website: https://www.masimo.com

Address: 52 Discovery Irvine, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Medical Instruments & Supplies

Masimo Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Masimo Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Glaukos Corporation GKOS $5.5 Billion
Tandem Diabetes Care, Inc. TNDM $3.1 Billion
DexCom, Inc. DXCM $52.2 Billion
LivaNova PLC LIVN $3.4 Billion
Insulet Corporation PODD $13.1 Billion
NuVasive, Inc. NUVA $2.1 Billion
Penumbra, Inc. PEN $7.9 Billion
CONMED Corporation CNMD $2.3 Billion
Inspire Medical Systems, Inc. INSP $4.6 Billion
ShockWave Medical, Inc. SWAV $12.4 Billion
TransMedics Group, Inc. TMDX $4.5 Billion
Inari Medical, Inc. NARI $2.7 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
MASI Income Statements
Quarter Year Revenue Earnings
Q4 2023 $ 548.9 Million $34.0 Million
Q3 2023 $ 478.9 Million $10.6 Million
Q2 2023 $ 455.3 Million $15.7 Million
Q1 2023 $ 565.0 Million $21.3 Million
Q4 2022 $ 617.0 Million $40.9 Million
Q3 2022 $ 549.3 Million $37.9 Million
Q2 2022 $ 565.3 Million $18.1 Million
Q1 2022 $ 304.2 Million $46.6 Million

View All

MASI Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2023 $163.0 Million $3.0 Billion $871.7 Million $1.4 Billion
Q3 2023 $124.4 Million $3.0 Billion $910.1 Million $1.3 Billion
Q2 2023 $150.7 Million $3.0 Billion $888.8 Million $1.3 Billion
Q1 2023 $174.1 Million $3.1 Billion $897.5 Million $1.3 Billion
Q4 2022 $202.9 Million $3.2 Billion $1.0 Billion $1.3 Billion
Q3 2022 $219.5 Million $3.1 Billion $951.4 Million $1.3 Billion
Q1 2022 $720.1 Million $1.9 Billion $0 $1.6 Billion
Q4 2021 $745.3 Million $1.9 Billion $32.7 Million $1.6 Billion

View All

MASI Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2023 $44.2 Million $0 $44.2 Million
Q3 2023 -$29.1 Million -$22.1 Million -$26.3 Million
Q2 2023 $1.5 Million -$22.1 Million -$22.5 Million
Q1 2023 -$17.8 Million -$18.2 Million -$28.5 Million
Q4 2022 -$13.0 Million -$6.4 Million -$12.5 Million
Q3 2022 $1.0 Million -$9.4 Million $1.5 Million
Q1 2022 $219,000 -$22.9 Million -$25.4 Million
Q4 2021 $91.5 Million -$6.1 Million $94.4 Million

View All